Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Moderna Says That FDA, Due To Administrative Constraints, Does Not Expect To Complete Its Review Of mRNA-1345, Respiratory Syncytial Virus Vaccine, By May 12, The FDA Has Informed Moderna That It Is Working To Conclude The Review By The End Of May

Author: Benzinga Newsdesk | May 10, 2024 07:06am

Posted In: MRNA